Media coverage about St Jude Medical (NYSE:STJ) has trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. St Jude Medical earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave news stories about the medical technology company an impact score of 96 out of 100, indicating that recent news coverage is extremely likely to have an impact on the stock’s share price in the near term.

St Jude Medical (STJ) traded up 0.16% during midday trading on Tuesday, hitting $80.82. 14,736,217 shares of the company were exchanged. St Jude Medical has a 1-year low of $48.83 and a 1-year high of $84.00. The stock has a 50 day moving average of $79.78 and a 200 day moving average of $79.88.

TRADEMARK VIOLATION WARNING: “St Jude Medical (STJ) Earning Somewhat Favorable Press Coverage, Report Shows” was originally published by Daily Political and is the property of of Daily Political. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at

About St Jude Medical

St. Jude Medical, Inc is focused on the development, manufacture and distribution of cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders.

Insider Buying and Selling by Quarter for St Jude Medical (NYSE:STJ)

Receive News & Ratings for St Jude Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for St Jude Medical Inc and related companies with's FREE daily email newsletter.